Table 1.
Characteristics of patients diagnosed with colorectal adenocarcinoma, 2010–12
|
Colon tumours |
Rectal tumours |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Denmark | England | Norway | Sweden | Denmark | England | Norway | Sweden | ||
| Mean age, years (SD) | 71·9 (11·3) | 72·4 (12·0) | 72·6 (11·9) | 72·7 (11·5) | 69·5 (11·5) | 70·0 (12·2) | 69·9 (12·2) | 70·3 (11·9) | |
| Age group, years | |||||||||
| 18–54 | 660 (7·7%) | 5700 (8·2%) | 656 (7·9%) | 863 (7·3%) | 481 (11·0%) | 3109 (11·3%) | 346 (11·1%) | 626 (10·8%) | |
| 55–64 | 1480 (17·3%) | 11 818 (16·9%) | 1345 (16·1%) | 1796 (15·2%) | 935 (21·3%) | 5936 (21·5%) | 679 (21·8%) | 1102 (19·0%) | |
| 65–74 | 2841 (33·2%) | 20 403 (29·2%) | 2441 (29·3%) | 3653 (31·0%) | 1502 (34·2%) | 8359 (30·3%) | 946 (30·4%) | 1900 (32·8%) | |
| 75–84 | 2567 (30·0%) | 21 942 (31·4%) | 2670 (32·0%) | 3907 (33·1%) | 1107 (25·2%) | 7289 (26·4%) | 809 (26·0%) | 1580 (27·3%) | |
| 85–99 | 1019 (11·9%) | 10 004 (14·3%) | 1227 (14·7%) | 1567 (13·3%) | 366 (8·3%) | 2906 (10·5%) | 331 (10·6%) | 589 (10·2%) | |
| Sex | |||||||||
| Men | 4160 (48·6%) | 37 279 (53·4%) | 4087 (49·0%) | 5875 (49·8%) | 2670 (60·8%) | 17 700 (64·1%) | 1836 (59·0%) | 3421 (59·0%) | |
| Women | 4407 (51·4%) | 32 588 (46·6%) | 4252 (51·0%) | 5911 (50·2%) | 1721 (39·2%) | 9899 (35·9%) | 1275 (41·0%) | 2376 (41·0%) | |
| Disease stage at diagnosis* | |||||||||
| Stage I | 839 (10·7%) | 7413 (12·8%) | 972 (13·0%) | 1462 (13·0%) | 793 (20·7%) | 5674 (24·4%) | 705 (26·0%) | 1247 (23·3%) | |
| Stage II | 2723 (34·7%) | 17 524 (30·3%) | 2482 (33·2%) | 3648 (32·5%) | 1032 (27·0%) | 5014 (21·6%) | 659 (24·3%) | 1264 (23·6%) | |
| Stage III | 2036 (25·9%) | 17 258 (29·8%) | 1931 (25·9%) | 3436 (30·6%) | 1062 (27·8%) | 7520 (32·4%) | 645 (23·8%) | 1551 (29·0%) | |
| Stage IV | 2256 (28·7%) | 15 679 (27·1%) | 2081 (27·9%) | 2670 (23·8%) | 935 (24·5%) | 5026 (21·6%) | 699 (25·8%) | 1294 (24·2%) | |
| Unknown stage | 713 (8·3%) | 11 993 (17·2%) | 873 (10·5%) | 570 (4·8%) | 569 (13·0%) | 4365 (15·8%) | 403 (13·0%) | 441 (7·6%) | |
| Received resectional surgery† | 6040 (70·5%) | 47 803 (68·4%) | 6023 (72·2%) | 9582 (81·3%) | 2982 (67·9%) | 16 544 (59·9%) | 2064 (66·3%) | 4106 (70·8%) | |
| Received radiotherapy‡ | 134 (1·6%) | 2097 (3·0%) | 109 (1·3%) | 54 (0·5%) | 1182 (26·9%) | 11 299 (40·9%) | 1321 (42·5%) | 2935 (50·6%) | |
| Received chemotherapy‡§ | 3272 (38·2%) | 18 640 (26·7%) | 1654 (19·8%) | 2525 (21·4%) | 2060 (46·9%) | 8484 (30·7%) | 931 (29·9%) | 1404 (24·2%) | |
| Unknown treatment status¶ | 949 (11·1%) | 214 (0·3%) | 0 (0·0%) | 0 (0·0%) | 263 (6·0%) | 67 (0·2%) | 0 (0·0%) | 0 (0·0%) | |
| Total | 8567 (100%) | 69 867 (100%) | 8339 (100%) | 11 786 (100%) | 4391 (100%) | 27 599 (100%) | 3111 (100%) | 5797 (100%) | |
Data are n (%), unless otherwise specified.
*
Proportions of total number of patients with known stage.
†
Defined as surgery to remove the primary tumour within 9 months of diagnosis, excluding diagnostic and palliative procedures.
‡
Received within 6 months of diagnosis; sources and completeness of information on chemotherapy or radiotherapy varied greatly between countries, with a high proportion of missing information in England.
§
Planned chemotherapy in Norway and Sweden.
¶
Proportion of patients not registered in specialised colorectal cancer registries (or Hospital Episode Statistics, Cancer Waiting Times Monitoring Data Set for England).